CD1a on Langerhans cells controls inflammatory skin disease

Area of Science:

• Immunology
• Dermatology
• Structural Biology

Background:

• CD1a is a lipid-presenting molecule on Langerhans cells, but its in vivo function is poorly understood due to its absence in mice.
• Urushiol, a plant-derived lipid, is known to cause allergic contact dermatitis.

Purpose of the Study:

• To elucidate the in vivo role of CD1a in skin inflammation.
• To identify the specific antigen recognized by CD1a and its mechanism of action.
• To evaluate CD1a as a therapeutic target for inflammatory skin conditions.

Main Methods:

• Utilized transgenic mice expressing CD1a to study urushiol-induced skin inflammation.
• Analyzed cytokine profiles (IL-17, IL-22) in T helper 17 (TH17) cells.
• Determined the crystal structure of the CD1a-urushiol complex.
• Investigated CD1a's role in mouse models and human psoriasis patients.
• Assessed the efficacy of anti-CD1a blocking antibodies.

Main Results:

• Transgenic mice showed CD1a-dependent skin inflammation mediated by TH17 cells upon urushiol exposure.
• Human poison-ivy dermatitis patients exhibited a similar TH17 cell cytokine signature.
• Diunsaturated pentadecylcatechol (C15:2) was identified as the dominant urushiol antigen for CD1a-restricted T cells.
• Crystal structure revealed the molecular basis of CD1a-C15:2 interaction.
• CD1a amplified inflammatory responses in psoriasis models, which were reduced by anti-CD1a antibodies.

Conclusions:

• CD1a plays a crucial role in initiating and amplifying skin inflammation, particularly through TH17 cell responses.
• CD1a-mediated recognition of urushiol and self-lipids contributes to inflammatory skin diseases.
• Blocking CD1a represents a promising therapeutic strategy for inflammatory skin conditions like psoriasis and allergic contact dermatitis.